Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
NCT03386214 · Washington University School of Medicine · PHASE1 · terminated · last registry update 2022-01-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor stopped development of pevonedistat” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against UBA3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-27Also stopped (terminated): M.D. Anderson Cancer Center, Pembrolizumab + Pevonedistat (NCT04800627)
- 2022-12-21Results posted on the registry: M.D. Anderson Cancer Center, Pembrolizumab + Pevonedistat (NCT04800627)
- 2022-09-23Results posted on the registry: Children's Oncology Group, Irinotecan + Pevonedistat (NCT03323034)
- 2022-09-22Results posted on the registry: Takeda, Azacitidine + Pevonedistat (NCT03268954)
- 2022-04-18Results posted on the registry: Millennium Pharmaceuticals, Inc., Pevonedistat + Rifampin (NCT03486314)
- 2021-09-29Also stopped (withdrawn): Takeda, Pevonedistat + Decitabine (NCT04985656)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision